QINLOCK
Total Payments
$72.3M
Transactions
21,705
Doctors
4,174
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $11.2M | 3,683 | 2,076 |
| 2023 | $5.9M | 4,791 | 1,651 |
| 2022 | $11.8M | 5,266 | 1,219 |
| 2021 | $33.2M | 7,225 | 1,310 |
| 2020 | $10.3M | 740 | 143 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $71.1M | 12,381 | 98.4% |
| Honoraria | $366,656 | 124 | 0.5% |
| Consulting Fee | $281,564 | 172 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $254,090 | 193 | 0.4% |
| Food and Beverage | $208,880 | 8,515 | 0.3% |
| Travel and Lodging | $79,135 | 295 | 0.1% |
| Education | $281.18 | 25 | 0.0% |
Payments by Type
Research
$71.1M
12,381 transactions
General
$1.2M
9,324 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | Deciphera Pharmaceuticals Inc. | $24.0M | 0 |
| INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | Deciphera Pharmaceuticals Inc. | $21.3M | 1 |
| INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES | Deciphera Pharmaceuticals Inc. | $6.6M | 0 |
| A STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GIST WITH SPECIFIC KIT EXON MUTATIONS WHO WERE PREVIOUSLY TREATED WITH IMATINIB (INSIGHT) | Deciphera Pharmaceuticals Inc. | $6.4M | 0 |
| A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE IN PATIENTS WITH ADVANCED GIST | Deciphera Pharmaceuticals Inc. | $5.8M | 0 |
| A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | Deciphera Pharmaceuticals Inc. | $5.1M | 0 |
| A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | Deciphera Pharmaceuticals Inc. | $926,709 | 0 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) | Deciphera Pharmaceuticals Inc. | $819,276 | 0 |
| PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) | Deciphera Pharmaceuticals Inc. | $114,485 | 0 |
| RIPRETINIB IN COMBINATION WITH BINIMETINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST) | Deciphera Pharmaceuticals Inc. | $67,419 | 0 |
| A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | Deciphera Pharmaceuticals Inc. | $34,697 | 0 |
| An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors | Deciphera Pharmaceuticals Inc. | $10,580 | 0 |
| EXPANDED ACCESS PROGRAM OF RIPRETINIB DCC-2618 FOR THE TREATMENT OF PATIENTS WITH ADVANCED GIST | Deciphera Pharmaceuticals Inc. | $5,261 | 0 |
Top Doctors Receiving Payments for QINLOCK — Page 167
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Sioux Falls, SD | $11.44 | 1 |
| , MD | Hematology & Oncology | Sioux Falls, SD | $11.44 | 1 |
| , MD | Specialist | Meridian, MS | $11.44 | 1 |
| , M.D | Hematology & Oncology | Miami, FL | $11.44 | 1 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $11.44 | 1 |
| , M.D | Hematology & Oncology | Meridian, MS | $11.44 | 1 |
| , M.D | Internal Medicine | Chicago, IL | $11.44 | 1 |
| Steven Kuross | Hematology | Duluth, MN | $11.44 | 1 |
| , M.D | Specialist | Meridian, MS | $11.44 | 1 |
| , M.D | Hematology & Oncology | Georgetown, SC | $11.44 | 1 |
| , MD | Medical Oncology | Rapid City, SD | $11.44 | 1 |
| , MD | Medical Oncology | Duluth, MN | $11.44 | 1 |
| , MD | Internal Medicine | Sioux Falls, SD | $11.44 | 1 |
| , MD | Otolaryngology | El Segundo, CA | $11.44 | 1 |
| , MD | Hematology & Oncology | Crestview, FL | $11.38 | 1 |
| , MD | Hematology & Oncology | Savannah, GA | $11.36 | 1 |
| , MD | Medical Oncology | Lake City, FL | $11.36 | 1 |
| , FNP | Family | Newnan, GA | $11.24 | 1 |
| , M.D | Surgical Oncology | Woodstock, GA | $11.24 | 1 |
| , APRN | Family | Newnan, GA | $11.24 | 1 |
| , NP | Family | Stockbridge, GA | $11.24 | 1 |
| , M.D | Hematology & Oncology | Southbridge, MA | $11.13 | 1 |
| , MD | Medical Oncology | Philadelphia, PA | $11.11 | 1 |
| , M.D | Hematology & Oncology | Savannah, GA | $11.08 | 1 |
| , NP-C | Emergency | Savannah, GA | $11.08 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $72.3M
- Total Doctors 4,174
- Transactions 21,705
About QINLOCK
QINLOCK is a drug associated with $72.3M in payments to 4,174 healthcare providers, recorded across 21,705 transactions in the CMS Open Payments database. The primary manufacturer is Deciphera Pharmaceuticals Inc..
Payment data is available from 2020 to 2024. In 2024, $11.2M was paid across 3,683 transactions to 2,076 doctors.
The most common payment nature for QINLOCK is "Unspecified" ($71.1M, 98.4% of total).
QINLOCK is associated with 13 research studies, including "A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES" ($24.0M).